News

Poseida Therapeutics Pursues New CAR-T Candidate with Roche Boost

Poseida Therapeutics Pursues New CAR-T Candidate with Roche Boost

Poseida Therapeutics Pursues New CAR-T Candidate with Roche Boost

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a pioneer in advanced allogeneic cell therapies and genetic medicines, recently announced the nomination of a promising new CAR-T development candidate in its ongoing collaboration with Roche. This significant milestone not only highlights Poseida's commitment to innovation but also triggers a milestone payment of $15 million from Roche, enhancing Poseida's cash runway into early 2026.

Introducing a New Dual CAR-T Therapy

The newly nominated candidate is an allogeneic, dual CAR-T therapy, specifically designed to target antigens known to be expressed in hematologic malignancies, including multiple myeloma. Thanks to Poseida's expert capabilities in non-viral transposon-based DNA delivery, the company is able to insert genes for dual chimeric antigen receptors (CARs) into T stem cell memory cells (TSCM), which could lead to more effective treatment outcomes.

Statements from Leadership

Kristin Yarema, Ph.D., the President and CEO of Poseida Therapeutics, expressed excitement about the nomination, stating, "This new candidate underscores the potential of our proprietary genetic engineering toolkit to advance TSCM-rich CAR-T therapies. With the rise in multiple myeloma cases and a profound need for effective treatments, we are eager to move forward through our collaboration with Roche. We look forward to sharing progress on this program and other initiatives during our upcoming Cell Therapy R&D Day."

Collaboration with Roche and Key Programs

This recent nomination adds to the already fruitful partnership between Poseida and Roche, which initiated in August 2022, focusing on developing allogeneic CAR-T therapies targeting various hematologic malignancies. The lead program from this collaboration, P-BCMA-ALLO1, has received the Regenerative Medicine Advanced Therapy (RMAT) designation, demonstrating its potential for adult patients who have relapsed or are refractory to multiple therapies. Poseida is currently enrolling patients in the Phase 1b trial for this therapy, with promising data reported.

Upcoming Events

Poseida is set to host its Cell Therapy R&D Day on November 14, 2024. This virtual event will showcase presentations from key management and expert scientists detailing advancements in Poseida's innovative CAR-T therapies and other projects aimed at both oncology and autoimmune disease treatments. The access to the event and live webcast will be provided through their official channels, promising an informative gathering for stakeholders and interested parties.

Financial Outlook

From a financial perspective, as of June 30, 2024, Poseida reported a robust cash position with $237.8 million in cash, cash equivalents, and short-term investments. The $15 million milestone payment from Roche, along with anticipated near-term payments under their collaboration agreement, is expected to support the company's operations and advancements through early 2026. Additional collaborations and business developments may further enhance their financial stability.

About Poseida Therapeutics, Inc.

Poseida Therapeutics stands as a clinical-stage biopharmaceutical company dedicated to developing cutting-edge allogeneic cell therapies and genetic medicines aimed at addressing significant unmet medical needs. Their pipeline highlights investigational therapies tailored for conditions spanning hematologic cancers to autoimmune diseases. With a strong foundation in proprietary genetic editing technologies, Poseida partners strategically with leaders like Roche to maximize the potential of their therapies to benefit cancer patients.

Frequently Asked Questions

What is the significance of the new CAR-T candidate for Poseida Therapeutics?

The new CAR-T candidate represents a major milestone, allowing Poseida to advance its innovative therapies for hematologic malignancies, enhancing its treatment portfolio.

How does the collaboration with Roche benefit Poseida's developments?

The collaboration provides Poseida with substantial financial support and allows access to Roche's expertise in drug development, increasing the chances of successful clinical outcomes.

When is the Poseida Cell Therapy R&D Day planned?

The Cell Therapy R&D Day is scheduled for November 14, 2024, where Poseida will present updates on its pipelines and research findings.

What are Poseida's main areas of focus in its therapy development?

Poseida focuses on allogeneic CAR-T therapies targeting hematologic cancers, autoimmune diseases, and solid tumors, underpinned by its proprietary genetic editing platforms.

What is the expected financial trajectory for Poseida Therapeutics?

With its current cash position and anticipated milestone payments, Poseida aims to sustain operations into 2026, focusing on advancing its clinical programs successfully.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 36

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 137

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
CVRx Lawsuit Puts a Brutal 59.76% Drop Under Focus

Updated Category News Views 33

Sixty cents on the dollar vanished from CVRx in one trading day, and that kind of wreckage deserves more than a shrug. Shares fell $3.55, or 59.76%, to $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. For holders of NASDAQ:CVRX, the immediate question is not whether the chart looks...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 87

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 7

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis Faces Setback as Entresto Generic Approved

Updated Category News Views 393

Novartis' Legal Challenges with Entresto Generic Novartis, a leading pharmaceutical company, recently encountered a significant setback in its attempts to block the launch of a generic version of its heart-failure medication, Entresto. A federal judge in Washington, D.C., ruled against Novartis', effectively paving the way for MSN Pharmaceuticals to release its generic...

Continue Reading
Walk-On's Partners with Port Royal for Expansive Growth

Updated Category News Views 581

Walk-On's Sports Bistreaux Announces Major Development Deal Walk-On's Sports Bistreaux is thrilled to announce a pivotal partnership with Port Royal Brands, marking a significant step forward in its expansion plans. This exciting collaboration will encompass the development of 20 new restaurants, aiming to bring the spirit of family-friendly sports dining to new...

Continue Reading
Gabelli Healthcare & Wellness Trust Announces Quarterly $0.17 Distribution

Updated Category News Views 152

Gabelli Healthcare & Wellness Trust Declares Cash Distribution The Board of Trustees of The Gabelli Healthcare & Wellness Trust (NYSE: GRX) has announced a cash distribution of $0.17 per share. This distribution is set to be paid to common shareholders on a specified date. The Board's decision reflects ongoing efforts to provide regular income to investors. Distribution...

Continue Reading
Faraday Future Prepares for Third Quarter Earnings Call

Updated Category News Views 119

Faraday Future Announces Earnings Conference Call Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) is excited to share the timeline for its scheduled earnings conference call focused on its third quarter results for 2024. This highly anticipated call will occur after market hours, specifically on a Wednesday evening, at 5:00 p.m. Pacific Time. Investors and...

Continue Reading
Chicagoland Leaders Rally to Support Local Black Businesses

Updated Category News Views 123

Community Leaders Unite for Local Black Businesses In a powerful display of solidarity, community leaders and clergy in Chicagoland are calling on the City Council to take decisive action in support of local Black-owned businesses. One business at the heart of this effort is Island Furs, a beloved fixture that has proudly served the community for over 30 years. The...

Continue Reading